Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abuse-Deterrent Opioids: FDA Advocates Joint Brand-Generic Development Plan

Executive Summary

Despite ‘tension’ between two industries over what is required to show generic is no less abuse-deterrent than innovator opioid, FDA’s Throckmorton suggests they come up with single approach to product development.


Related Content

Final Generic Abuse-Deterrent Opioids Guidance Coming This Year
Abuse Deterrence: US Exclusivity Update May Ride User Fee Coattails
Purdue Is Open For Business Deals And Shopping On Multiple Fronts
ANDAs Can Get Priority, Eight-Month Reviews Under User Fee Deal
KemPharm Seeks FDA Dispute Resolution Over Apadaz's Abuse Deterrence
Abuse-Deterrent Opioids Effectiveness, Value To Get ICER Review
Can KemPharm's Apadaz Meet FDA Opioid Abuse Deterrent Standards?
Abuse-Deterrent Opioids: Generics Worry Comparator Standard Impedes Approvals
Generic Abuse Deterrent Opioids: FDA Offers Tier-Based Testing Approach
Abuse-Deterrent Opioids Could Gain Significant First-Mover Advantage Under FDA Guidance


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts